| Business Summary | | PhotoMedex,
Inc.
develops,
manufactures,
and
markets
therapeutic
excimer
laser-based
instrumentation
designed
to
treat
psoriasis
and
vitiligo.
The
Company's
excimer
laser
system,
XTRAC
system,
is
indicated
for
the
treatment
of
psoriasis.
The
Company
also
developed
AL5000M,
or
Transmyocardial
revascularization,
a
new,
FDA-approved
method
of
relieving
debilitating
pain
in
patients
suffering
from
angina.
PhotoMedex
currently
does
not
have
a
strategic
partner
with
whom
to
market
its
AL5000M,
and
the
Company
does
not
currently
have
sufficient
financial
resources
to
commercialize
the
AL5000M
by
itself. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | PhotoMedex,
Inc.
is
engaged
in
the
development
of
proprietary
excimer
laser
and
fiber
optic
equipment
and
techniques
directed
toward
the
treatment
of
cardiovascular
and
vascular
disease
and
the
treatment
of
psoriasis.
For
the
six
months
ended
6/30/01,
revenue
totaled
$3.3
million,
up
from
$570
thousand.
Net
loss
from
continuing
operations
rose
34%
to
$7.2
million.
Results
reflect
the
sale
of
lasers
to
an
international
distributor,
offset
by
higher
consulting
fees. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Warwick Charlton, 41 Chairman | -- | -- | Jeffrey O'Donnell, 41 Pres,
CEO, Director | $424K | $1.0M | Dennis McGrath, 44 CFO,
VP of Fin. and Admin. | 300K | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|